Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property develo
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ ... help predict the adverse and therapeutic effects of a ... Computational Biology at the Genomics Laboratory, Covance, will discuss ... genomics when used as part of the QC process. ... sets to identify key clinical targets even in complex ...
(Date:5/16/2013)... OH (PRWEB) May 16, 2013 The ... manufactured by Global Cooling, Inc., Athens, OH, USA, won ... 2013 by the International Society for Biological and Environmental ... The award, given to one product annually, recognizes the ... efficient ultra-low temperature freezer. The award was presented ...
(Date:5/16/2013)... Mass. (PRWEB) May 16, 2013 Cambridge ... Summit from August 19-23, 2013 at the Renaissance Waterfront ... the Summit provide a close-up look at the current ... and ensuring bottom-line quality. Leaders in the field ... ways to produce biopharmaceuticals with greater specificity and efficiency. ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2
... , SEATTLE, Nov. 11 Dendreon Corporation (Nasdaq: DNDN ... 2009. Revenue for the third quarter of 2009 was $25,000 ... Revenue for the nine months ended September 30, 2009 was ... 30, 2008. , Dendreon,s total operating expenses for the ...
... MADRID, November 11 Cellerix, a ... today announced the successful first closing of its financing ... current,shareholders and a select group of new investors. Cellerix ... , This round was led ...
... AMSTERDAM, November 11 Amsterdam ... human gene therapy,announced today that it has successfully treated ... proprietary gene therapy. The proof of,concept studies were performed ... of Rome, La Sapienza, Italy) and demonstrated,effectiveness in the ...
Cached Biology Technology:Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 6Cellerix Raises EUR27 Million in a First Closing 2AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Jersey, and City University of New York have invented ... effectively clears organisms to be viewed under microscopes. Visikol ... is one of the few high-quality clearing solutions currently ... Enforcement Administration (DEA) due to its use as a ... for viewing organisms under a microscope. Without them, microscope ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... calculated that the bite force of the great white,s ... (also known as Big Tooth) is the highest ... carnivore ever to have existed. Shark researchers from ... Department of Primary Industries Fisheries (Australia) and University of ...
... Fruit and Vegetable Consumption Is Low among Black Men ... fruits and vegetables, daily consumption of these foods among ... researchers at Columbia and Temple universities, the University of ... study of 490 American and foreign-born black men between ...
... - JDRF said today that it has recognized the work ... the pace of science in understanding the autoimmune attack that ... severe complications of this chronic and life-threatening disease. ... Dr. Jeffrey A. Bluestone, Director of the Diabetes Center at ...
Cached Biology News:Great white's mighty bite revealed 2Highlights from the August 2008 Journal of the American Dietetic Association 2JDRF announces 2008 Scholar Award recipients 2JDRF announces 2008 Scholar Award recipients 3
...
... Grace's medium was originally formulated to support ... Australian emperor gum moth,Antherea eucalypti. The medium ... more closely resembleAnthereahemolymph. The cell lines established ... first continuous lines developed. The basal medium, ...
... and Digital Orbital Shaker. Our durable, rugged VSOS-4 ... every day use even easier. This advanced Orbital ... 4 different programs. Its easy recall function allows ... VSOS-4P has a pulse operation for a short ...
... The MONOLIGHT 3096 Microplate Luminometer ... chemi- and bioluminescence and for,all measurements ... microplates,i.e. for reactions where the light ... of time, as well as for ...
Biology Products: